By Joe Hoppe

AstraZeneca PLC said Thursday that a Phase 3 trial showed that its Imfinzi product significantly improved event-free survival in patients with resectable non-small cell lung cancer.

The Anglo-Swedish pharma major said the positive high-level results from an interim analysis of the AEGEAN trial showed treatment using Imfinzi coupled with chemotherapy before surgery and monotherapy showed statistically significant and clinically meaningful improvement in the time patients live without recurrence or progression events.

The drug was well-tolerated and no new safety concerns were observed. It didn't increase complications or adverse events nor compromised patients' abilities to undergo surgery when compared with chemotherapy alone.

The company said separately that its Tagrisso cancer drug's first Phase 3 trial showed a statistically significant and clinically meaningful improvement in overall survival in treating patients with early-stage non-small cell lung cancer after tumor resection when compared with placebo.

Tagrisso's safety and tolerability was also consistent with its established profile and no new safety concerns were reported.

Write to Joe Hoppe at joseph.hoppe@wsj.com

(END) Dow Jones Newswires

March 09, 2023 03:14 ET (08:14 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mag 2023 a Giu 2023 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Giu 2022 a Giu 2023 Clicca qui per i Grafici di Astrazeneca